A carregar...
Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial
INTRODUCTION: Infliximab (IFX), a monoclonal chimeric antibody against tumour necrosis factor (TNF) α, is effective for induction and maintenance of remission in moderate to severe Crohn's disease. Discontinuation of IFX maintenance therapy in patients in remission should be considered in order...
Na minha lista:
| Publicado no: | BMJ Open |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4275671/ https://ncbi.nlm.nih.gov/pubmed/25524543 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2014-005887 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|